Amylyx Withdraws ALS Drug Relyvrio After Failing Key Study

The drug's removal, following a large trial showing no patient benefits, leaves limited treatment options for ALS patients.

Amylyx Pharmaceuticals will withdraw its ALS drug Relyvrio from the US and Canadian markets after a large study showed no patient benefits.
Patients currently on Relyvrio can continue receiving the drug for free through a company program.
The FDA had granted Relyvrio full approval in 2022 despite questions about its efficacy, based on a single, small trial.
Relyvrio's withdrawal leaves only three ALS treatments available in the US, with only one shown to extend survival.
Amylyx plans to lay off 70% of its workforce and will continue researching other treatments for neurodegenerative diseases.